Neil Chatterji
Stock Analyst at B. Riley Securities
(1.02)
# 3,554
Out of 4,827 analysts
17
Total ratings
25%
Success rate
-5.99%
Average return
Main Sectors:
Stocks Rated by Neil Chatterji
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLPT ClearPoint Neuro | Maintains: Buy | $15 → $20 | $14.25 | +40.35% | 2 | Jan 28, 2025 | |
| OPRX OptimizeRx | Maintains: Buy | $17 → $13 | $9.91 | +31.18% | 3 | Dec 24, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $95 → $50 | $34.80 | +43.68% | 2 | Nov 9, 2023 | |
| ARAY Accuray | Reiterates: Buy | $7.5 | $1.49 | +403.36% | 1 | Oct 4, 2023 | |
| ZUMZ Zumiez | Maintains: Neutral | $15 → $18 | $12.31 | +46.22% | 2 | Sep 8, 2023 | |
| KRMD KORU Medical Systems | Initiates: Buy | $4.5 | $3.29 | +36.78% | 1 | Sep 7, 2023 | |
| HYPR Hyperfine | Maintains: Buy | $2.5 → $3.5 | $0.72 | +386.65% | 3 | Aug 15, 2023 | |
| STXS Stereotaxis | Maintains: Buy | $6 → $5.5 | $2.16 | +154.63% | 2 | Mar 6, 2023 | |
| BFLY Butterfly Network | Initiates: Buy | $9.5 | $2.27 | +318.50% | 1 | Oct 4, 2022 |
ClearPoint Neuro
Jan 28, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $14.25
Upside: +40.35%
OptimizeRx
Dec 24, 2024
Maintains: Buy
Price Target: $17 → $13
Current: $9.91
Upside: +31.18%
Establishment Labs Holdings
Nov 9, 2023
Maintains: Buy
Price Target: $95 → $50
Current: $34.80
Upside: +43.68%
Accuray
Oct 4, 2023
Reiterates: Buy
Price Target: $7.5
Current: $1.49
Upside: +403.36%
Zumiez
Sep 8, 2023
Maintains: Neutral
Price Target: $15 → $18
Current: $12.31
Upside: +46.22%
KORU Medical Systems
Sep 7, 2023
Initiates: Buy
Price Target: $4.5
Current: $3.29
Upside: +36.78%
Hyperfine
Aug 15, 2023
Maintains: Buy
Price Target: $2.5 → $3.5
Current: $0.72
Upside: +386.65%
Stereotaxis
Mar 6, 2023
Maintains: Buy
Price Target: $6 → $5.5
Current: $2.16
Upside: +154.63%
Butterfly Network
Oct 4, 2022
Initiates: Buy
Price Target: $9.5
Current: $2.27
Upside: +318.50%